Truly hope you're right - just can't see PER being at $1.12 SP (based on $1B MC) in seven months without MAJOR news of a buyer, approval, results, etc.
I believe in ATL1102, and have a large stake but maybe we need to calm the horses down with SP predictions unless they are based on facts.
Things coming in 2024 for PER...
1. ATL1102 - 9 month toxicology study: final study report due mid-2024. This could lead to a US FDA Fast Track designation. This delivers a $100K approx. value to PER if we sold the fast track to another company.
## this is the possible driver of SP for this year?! ##
2. ATL1102 phase IIb clinical trial: recruitment to complete at end of March 2024. First dosing shortly after of the those recruits. 12 months from there PLUS time to collate - results collated and released. Results expected mid-2025??
## clinical trial can be monitored via disclosures such as any dropouts or negative reactions ## The longer we go without negative, the more the SP will react and anticipate.
We are cheap in my books.
- Forums
- ASX - By Stock
- PER
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-66
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.0¢ |
Change
0.004(4.65%) |
Mkt cap ! $81.13M |
Open | High | Low | Value | Volume |
8.6¢ | 9.1¢ | 8.5¢ | $181.6K | 2.049M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10344 | 8.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.0¢ | 64275 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.085 |
2 | 155000 | 0.084 |
1 | 150000 | 0.083 |
1 | 36585 | 0.082 |
3 | 43077 | 0.081 |
Price($) | Vol. | No. |
---|---|---|
0.090 | 64275 | 1 |
0.091 | 106821 | 1 |
0.092 | 50000 | 1 |
0.094 | 160000 | 1 |
0.095 | 550000 | 2 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online